What is Augma Biomaterials?
Augma Biomaterials operates at the intersection of biotechnology and clinical dentistry, providing a comprehensive suite of bone grafting solutions. The company's product portfolio, which includes proprietary bone graft cement, collagen plugs, and specialized degranulation kits, is engineered to address the complex needs of dental professionals performing socket grafting, sinus lifts, and full arch reconstruction. Beyond its hardware offerings, Augma distinguishes itself through a commitment to clinical excellence, providing extensive educational resources, webinars, and professional development courses. This integrated approach ensures that practitioners are not only equipped with high-performance materials but also the technical expertise required for successful bone regeneration outcomes.
How much funding has Augma Biomaterials raised?
Augma Biomaterials has raised a total of $25K across 1 funding round:
Debt
$25K
Debt (2021): $25K with participation from PPP
Key Investors in Augma Biomaterials
PPP
Public-Private Partnership
What's next for Augma Biomaterials?
With the recent infusion of capital, Augma Biomaterials is poised to accelerate its strategic roadmap, focusing on market penetration and the potential expansion of its regenerative product pipeline. The company is expected to utilize these funds to enhance its distribution networks and broaden its educational outreach, thereby increasing its footprint in the global dental market. As the demand for minimally invasive and effective bone grafting procedures continues to rise, Augma's focus on innovation and practitioner support positions it to capture significant market share. Future growth will likely be driven by continued investment in research and development, ensuring the firm remains at the forefront of dental biomaterials technology.
See full Augma Biomaterials company page
